Erufosine - CAS 202867-33-2

Erufosine is an inhibitor of the PI3K/Akt and Ras/Raf/MAPK signaling pathways. It suppresses the activity of breast cancer cell lines MCF-7 and MDA-MB 231 with an IC50 of 40.95/40.8 μM, respectively. Erufosine reduces phosphorylation of PI3K (p85), Akt (PKB), and cRaf, making it applicable in research on breast cancer and myeloid leukemia.

Raf, Ras, Akt, p38 MAPK, PI3K

PI3K/Akt/mTOR signaling, MAPK, Cytoskeletal Signaling

202832

C28H58NO4P

503.74

P(OCCCCCCCCCCCC/C=C\CCCCCCCC)(OCCC[N+](C)(C)C)(=O)[O-]

-20°C

Ice Packs

Small Compound